Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.

abstract：:Cyclophosphamide (Cy) is widely used as an effective cytotoxic drug, but its use is limited because of its toxicity. In this report, we describe for the first time the ability of purified protein A (P) of Staphylococcus aureus to reduce Cy-induced toxicity in rats. Protein A-treated animals recover quickly from the to...

journal_title：Cancer chemotherapy and pharmacology

authors： Ray PK,Dohadwala M,Bandyopadhyay SK,Canchanapan P,McLaughlin D

更新日期：1985-01-01 00:00:00

abstract：:The cellular metabolism of 3'-amino-2',3'-dideoxycytidine (3'-NH2-dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside (ara-C) in cells that displayed dCydD activity (HeLa) and in cells that did not (L1210). Growth i...

journal_title：Cancer chemotherapy and pharmacology

authors： Mancini WR

更新日期：1992-01-01 00:00:00

abstract：:To evaluate the antiemetic efficacy of high-dose methylprednisolone (MP) in previously untreated cancer patients receiving cisplatin (CPDD) for the first time, we performed a randomized double blind study. MP or a placebo (PLB) was administered six times during each course of chemotherapy. The first dose was 500 mg an...

journal_title：Cancer chemotherapy and pharmacology

authors： Schallier D,Van Belle S,De Greve J,Willekens A

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

journal_title：Cancer chemotherapy and pharmacology

authors： Hurtubise A,Momparler RL

更新日期：2006-11-01 00:00:00

abstract：:The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Krivit W,Chilcote R,Pyesmany A,Anderson J,Hammond D

更新日期：1979-01-01 00:00:00

abstract：:Sorafenib (Nexavar®) is currently the only FDA-approved small molecule targeted therapy for advanced hepatocellular carcinoma. The use of structural analogues and derivatives of sorafenib has enabled the elucidation of critical targets and mechanism(s) of cell death for human cancer lines. We previously performed a st...

journal_title：Cancer chemotherapy and pharmacology

authors： Wecksler AT,Hwang SH,Liu JY,Wettersten HI,Morisseau C,Wu J,Weiss RH,Hammock BD

更新日期：2015-01-01 00:00:00

abstract：PURPOSE:Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Peer CJ,Schmidt KT,Kindrick JD,Eisner JR,Brown VV,Baskin-Bey E,Madan R,Figg WD

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Masuda H,Masuda N,Kodama Y,Ogawa M,Karita M,Yamamura J,Tsukuda K,Doihara H,Miyoshi S,Mano M,Nakamori S,Tsujinaka T

更新日期：2011-04-01 00:00:00

abstract：BACKGROUND:Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been identified. Our aim was to investigate the association between ...

journal_title：Cancer chemotherapy and pharmacology

authors： Crucitta S,Del Re M,Paolieri F,Bloise F,Sbrana A,Sammarco E,Mercinelli C,Cucchiara F,Fontanelli L,Galli L,Danesi R

更新日期：2020-10-01 00:00:00

abstract：PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

journal_title：Cancer chemotherapy and pharmacology

authors： Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

更新日期：2014-04-01 00:00:00

abstract：:A sensitive solid-phase-extraction and high-performance liquid chromatography (HPLC) method has been developed to investigate the pharmacokinetics and metabolism of the hypoxic-cell cytotoxic agent tirapazamine (1,2,4-benzotriazine-3-amine 1,4-di-N-oxide; WIN 59075, SR 4233), currently in phase I/II studies in the Uni...

journal_title：Cancer chemotherapy and pharmacology

authors： Robin H Jr,Senan S,Workman P,Graham MA

更新日期：1995-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the response rate, methotrexate plasma levels, and toxicity of a three-drug regimen in patients with gastric carcinoma. A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF). Adriamyci...

journal_title：Cancer chemotherapy and pharmacology

authors： Ajani JA,Goudeau P,Levin B,Faintuch JS,Abbruzzese JL,Boman BM,Kanojia MD

更新日期：1989-01-01 00:00:00

abstract：:Male Sprague-Dawley rats were given single i.p. injections of 1,3-bis(2-chloroethyl)-1-Nitrosourea (BCNU) to investigate changes in hepatic microsomal cytochrome P-450 content and metabolic activity. On day 14 after treatment (20 mg/kg), cytochrome P-450 content had decreased by approximately 25% and ethylmorphine N-d...

journal_title：Cancer chemotherapy and pharmacology

authors： Stolzenbach JC,Larson RE

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:Nephrotoxicity is one of the major dose-limiting side-effects of cisplatin (DDP). The disproportionate accumulation of cisplatin in kidney tissue may play an important role, however, therapeutic measures to prevent this prime cause of nephrotoxicity are not available. Because certain amino acids (AAs) have been...

journal_title：Cancer chemotherapy and pharmacology

authors： Kröning R,Lichtenstein AK,Nagami GT

更新日期：2000-01-01 00:00:00

abstract：:While N-phosphonacetyl-L-aspartic acid (PALA), an inhibitor of de novo pyrimidine biosynthesis, demonstrated a unique spectrum of activity during preclinical drug evaluation, multiple clinical trials have shown it to possess minimal clinical activity. One explanation for the disappointing results is the possibility th...

journal_title：Cancer chemotherapy and pharmacology

authors： Markman M,Chan TC,Cleary S,Howell SB

更新日期：1987-01-01 00:00:00

abstract：:This phase I study was carried out to determine the maximal tolerated dose of carboplatin (Car) together with a fixed dose of etoposide (E) and to recommend the optimal dose for a phase II study. The dose of E was 100 mg/m2 given i.v. on days 1-3, and the starting dose of Car was 200 mg/m2 given i.v. on day 1. The dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Liippo K,Nikkanen V,Heinonen E

更新日期：1990-01-01 00:00:00

abstract：:The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin (BCG) for prophylaxis of recurrence of superficial bladder cancer (pTa, pT1) were investigated in 29 patients aged a median of 70 years between January of 1991 and May of 1993. The patients received intravesical instillation of...

journal_title：Cancer chemotherapy and pharmacology

authors： Uekado Y,Hirano A,Shinka T,Ohkawa T

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Pharmacokinetic-pharmacodynamic (PK-PD) models able to predict the action of anticancer compounds in tumor xenografts have an important impact on drug development. In case of anti-angiogenic compounds, many of the available models show difficulties in their applications, as they are based on a cell kill hypothe...

journal_title：Cancer chemotherapy and pharmacology

authors： Rocchetti M,Germani M,Del Bene F,Poggesi I,Magni P,Pesenti E,De Nicolao G

更新日期：2013-05-01 00:00:00

abstract：:The 9L gliosarcoma growing subcutaneously in the hind leg of the Fisher 344 rat contains major areas of severe (< 5 mmHg) hypoxia, making up about 49% of the tumor. Intravenous administration of an ultrapurified polymerized bovine hemoglobin solution (8 ml/kg) along with normal air breathing reduces the percentage of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Teicher BA,Holden SA,Menon K,Hopkins RE,Gawryl MS

更新日期：1993-01-01 00:00:00

abstract：:We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

journal_title：Cancer chemotherapy and pharmacology

authors： Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:To compare the response, survival, hematological and non-hematological toxicities of gemcitabine administrated at fixed-dose rate infusion (10 mg/m(2)/min, FDR) and standard 30 min infusion in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Electronic databases of MEDLINE, EMBASE and Cochran...

journal_title：Cancer chemotherapy and pharmacology

authors： Qiu MT,Ding XX,Hu JW,Tian HY,Yin R,Xu L

更新日期：2012-12-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：OBJECTIVE:Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pothuri B,Brodsky AL,Sparano JA,Blank SV,Kim M,Hershman DL,Tiersten A,Kiesel BF,Beumer JH,Liebes L,Muggia F

更新日期：2020-04-01 00:00:00

abstract：:A dose-ranging study with oral levonantradol was performed in 20 cancer patients. The optimum oral dose which attenuated vomiting accompanying chemotherapy was 1 mg 4-hourly. Side-effects comprised dizziness, confusion, euphoria, drowsiness, and difficulty in concentrating. There was no cardiovascular toxicity. Overal...

journal_title：Cancer chemotherapy and pharmacology

authors： Welsh J,Stuart F,Sangster G,Milstead R,Kaye S,Cash H,Charlton D,Calman K

更新日期：1983-01-01 00:00:00

abstract：:The activity of CD437¿6-[3-(1-adamantyl)-4 hydroxyphenyl]-2-naphthalene carboxylic acid¿, a relatively selective activator of RAR-gamma, was evaluated against four human ovarian-carcinoma cell lines : PE01, PE04 (a Pt-resistant in vivo-derived counterpart of PE01), PE01CDDP (a Pt-resistant in vitro-derived model of PE...

journal_title：Cancer chemotherapy and pharmacology

authors： Langdon SP,Rabiasz GJ,Ritchie AA,Reichert U,Buchan P,Miller WR,Smyth JF

更新日期：1998-01-01 00:00:00

abstract：:The purpose of the present study was to determine the maximally tolerated dose of thioTEPA given with fixed high-dose cyclophosphamide (CPA) and cisplatin (cDDP) followed by autologous bone marrow (ABM) with or without granulocyte colony-stimulating factor (G-CSF)-primed peripheral-blood progenitor cells (PBPCs) in pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Hussein AM,Petros WP,Ross M,Vredenburgh JJ,Affrontil ML,Jones RB,Shpall EJ,Rubin P,Elkordy M,Gilbert C,Gupton C,Egorin MJ,Soper J,Berchuck A,Clarke-Person D,Berry DA,Peters WP

更新日期：1996-01-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hemopoietic development and is invariably associated with reciprocal chromosomal translocations involving the retinoic acid receptor alpha (RARalpha) gene on chromosome 17. RARalpha var...

journal_title：Cancer chemotherapy and pharmacology

authors： Pandolfi PP

更新日期：2001-08-01 00:00:00

abstract：PURPOSE:A refined pharmacodynamic model for toxicity is necessary for successful adaptive control of the administration of an anticancer drug to avoid toxicity. We sought to establish a pharmacodynamic model of leukopenia in a 14-day administration of etoposide. METHODS:Pharmacokinetic data of 32 patients treated with...

journal_title：Cancer chemotherapy and pharmacology

authors： Minami H,Ratain MJ,Ando Y,Shimokata K

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors. METHODS:Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either...

journal_title：Cancer chemotherapy and pharmacology

authors： Low JC,Wasan KM,Fazli L,Eberding A,Adomat H,Guns ES

更新日期：2007-11-01 00:00:00

abstract：PURPOSE:The present study aims to establish a method that provides fast, precise and reproducible pharmacokinetic (PK) parameters of antibody-calicheamicin conjugates. The method should discriminate between PK of the antibody moiety and PK of the conjugated calicheamicin (CM). METHODS:The conjugates gemtuzumab ozogami...

journal_title：Cancer chemotherapy and pharmacology

authors： Boghaert ER,Khandke KM,Sridharan L,Dougher M,DiJoseph JF,Kunz A,Hamann PR,Moran J,Chaudhary I,Damle NK

更新日期：2008-05-01 00:00:00